| Regulatory Rapporteur February 2021 | MEMBERS |
| Advanced therapies and regenerative medicines regulation – part II: the US | MEMBERS |
| Fixed-dose combination products – the regulatory landscape in the US, the EU and its evolution in India | MEMBERS |
| Can Chinese Phase I data from the West accelerate China drug development? The science of ethnobridging | MEMBERS |
| Industry’s experience on ACSS regulatory worksharing pilot | MEMBERS |
| Reliability standards for Japanese marketing approval applications | MEMBERS |
| Advertising cosmetics versus medicines: a comparative analysis across markets | MEMBERS |
| A review of IDMP and SPOR data management services | MEMBERS |